Company Description
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis.
The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers.
It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis.
The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021.
Statera Biopharma, Inc. is based in Fort Collins, Colorado.
| Country | Colombia |
| Founded | 2013 |
| IPO Date | Jul 21, 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 46 |
| CEO | Michael Kevin Handley |
Contact Details
Address: 2537 Research Boulevard, Suite 201 Fort Collins, Colorado 80526 United States | |
| Phone | (888) 613-8802 |
| Website | staterabiopharma.com |
Stock Details
| Ticker Symbol | STAB |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001318641 |
| CUSIP Number | 857561104 |
| ISIN Number | US8575611046 |
| Employer ID | 20-0077155 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael Kevin Handley | Chief Executive Officer, President and Chairman of the Board |
| Christopher Zosh | Executive Vice President of Finance, Interim Principal Financial Officer and Interim Principal Accounting Officer |
| Dr. Robert W. Buckheit Jr., Ph.D. | Chief Technology Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 3, 2023 | 25-NSE | Filing |
| Mar 1, 2023 | DEFR14A | Filing |
| Feb 27, 2023 | DEF 14A | Other definitive proxy statements |
| Feb 14, 2023 | PRE 14A | Other preliminary proxy statements |
| Feb 1, 2023 | 8-K | Current Report |
| Feb 1, 2023 | 8-A12G | Filing |
| Jan 20, 2023 | 8-K | Current Report |
| Nov 28, 2022 | DEF 14A | Other definitive proxy statements |
| Nov 18, 2022 | PRE 14A | Other preliminary proxy statements |
| Nov 15, 2022 | 8-K | Current Report |